BACKGROUND: According to 3 randomized trials, the levonorgestrelreleasing intrauterine system significantly reduced recurrent endometriosis-related pelvic pain at postoperative year 1. Only a few studies have evaluated the long-term effectiveness of the device for preventing endometrioma recurrence, and the effects of a levonorgestrelreleasing intrauterine system as a maintenance therapy remain unclear. OBJECTIVE: The objective of the study was to evaluate whether a maintenance levonorgestrel-releasing intrauterine system is effective for preventing postoperative endometrioma recurrence. STUDY DESIGN: From May 2011 through March 2012, a randomized controlled trial including 80 patients with endometriomas undergoing laparoscopic cystectomy followed by six cycles of gonadotropin-releasing hormone agonist treatment was conducted. After surgery, the patients were randomized to groups that did or did not receive a levonorgestrelreleasing intrauterine system (intervention group, n ¼ 40, vs control group, n ¼ 40). The primary outcome was endometrioma recurrence 30 months after surgery. The secondary outcomes included dysmenorrhea, CA125 levels, noncyclic pelvic pain, and side effects. RESULTS: Endometrioma recurrence at 30 months did not significantly differ between the 2 groups (the intervention group, 10 of 40, 25% vs the control group 15 of 40, 37.5%; hazard ratio, 0.60, 95% confidence
Postoperative medical therapies have been considered to reduce surgical treatment failures. [3] [4] [5] Current postoperative hormonal treatments include gonadotropin-releasing hormone agonists (GnRHas), progestin, and combined oral contraceptives (OC). [6] [7] [8] [9] However, endometriosisassociated pain symptoms usually return after the cessation of postoperative hormonal therapy. 10 For example, the long-term recurrence rates reported 5 years after therapy with GnRHas are more than 40% for patients with endometrioma. 11 Thus, maintenance therapy for endometriosis is a reasonable approach for prolonging the recurrence-free period.
The levonorgestrel-releasing intrauterine system (Mirena; Bayer Ag, Turku, Finland) is a suitable medical device for maintenance therapy because it directly delivers 20 mg/d of levonorgestrel into the uterine cavity over its 5 year life span. 12 According to 3 randomized trials, the device significantly reduced recurrent endometriosis-related pelvic pain at postoperative year 1. 4, 6, 13 One retrospective study showed that the device provided symptom control for laparoscopically confirmed endometriosis throughout the 3 year study period.
14 Few studies have evaluated the long-term effectiveness of the device for preventing endometrioma recurrence, 15, 16 and the effects of the levonorgestrel-releasing intrauterine system maintenance therapy remain unclear.
The objective of our study was to examine the efficacy of postoperative levonorgestrel-releasing intrauterine system maintenance therapy for preventing endometrioma recurrence.
Materials and Methods
The study was designed as a prospective, randomized, controlled clinical The study protocol was approved by the Institutional Review Board of Taipei Veterans General Hospital, Taiwan, R.O.C. (VGHIRB: 97-04-03). This trial was registered with clinicaltrials.gov, www.clinicaltrials.gov (NCT01125488). Informed consent was obtained from all patients.
The sample size was calculated using a formula to compare 2 proportions. Based on an alpha of 0.05, a power of 0.80, recurrent endometriomas proportions of 0.30 for the control group 11 and 0.05 for the intervention group, 15 equal sizes for both groups, and a 2-tailed test, and the sample size required for each group was 39.
Women with dysmenorrhea and a sonographic diagnosis of endometrioma who were scheduled for elective laparoscopic ovarian cystectomy surgery were included in the study. The patients selected for screening were the consecutive patients of 1 study surgeon (Y.-J.C.) who required laparoscopic cystectomy during the study period.
The inclusion criterion was moderate and severe symptomatic endometriosis (stages 3 and 4) according to the revised American Society for Reproductive Medicine (ASRM) classification, with a chocolate-containing cyst observed during laparoscopic surgery.
The exclusion criteria included the desire to become pregnant within 30 months, age <20 years or >43 years, the inability to undergo conservative surgery, any hormonal therapy within the 3 months preceding surgery, a history of previous surgery for endometriosis, the use of GnRHas, a clinical history of pelvic inflammatory disease, uterine and adnexal pathologies other than endometrioma (eg, adenomyosis, leiomyoma, other ovarian pathologies), and other contraindications for the use of the levonorgestrel-releasing intrauterine system. 6 Laparoscopy was performed under general anesthesia using the 4-puncture technique. The severity of endometriosis was evaluated using the ASRM classification of endometriosis, and staging was performed intraoperatively by 2 experienced surgeons (Y.-J.C. and H.-W.T.) who were involved in the operations.
Computer-generated random numbers in sequentially sealed opaque envelopes were used to randomly allocate the patients into either the control group (n ¼ 40) or the intervention group (n ¼ 40).
All the subjects underwent laparoscopic ovarian cystectomy and received postoperative GnRHa injections every 4 weeks for 6 months ( Figure 1) . The operations were performed using only mechanical instruments and electrosurgery. 17 Adhesions were dissected and the ovaries were completely mobilized. The endometriomas were evacuated and excised using countertraction applied to the pseudocapsule and the normal ovarian tissue. Bleeding was stopped with the limited application of a bipolar current. Remaining fragments of the ovarian endometrioma wall were fulgurated using electrocauterization. 17 After the laparoscopic cystectomy was completed and before anesthesia was reversed, the patients were allocated to either group. For those in the intervention group, a levonorgestrel-releasing intrauterine system was inserted into the uterine cavity by the surgeon while the patient was still unconscious under general anesthesia. 
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Specimens were submitted for histopathological evaluation to confirm the presence of endometriosis in all patients. Within 3 days after surgery for endometriosis, a GnRHa was administered. 18 The patients in both groups received a GnRHa in 3.75 mg leuprorelin acetate intramuscularly (Enantone; Takeda IMC Ltd, Takeda, Japan) once every 4 weeks for 6 doses. The contraception method for the control group was condoms and periodic abstinence.
The collected baseline information included age, parity, body mass index (calculated as weight (kilograms)/ [height (meters)] 2 ), endometriosis stage according to the revised ASRM classification, and the severity of pelvic pain, including dysmenorrhea and noncyclic pelvic pain.
Transvaginal ultrasonography demonstrating ovarian endometrioma and the CA125 levels in the follicular phase were obtained to confirm the diagnosis. 19 Dysmenorrhea and noncyclic pelvic pain were measured using a linear visual analog scale (VAS). 20 In the present study, dysmenorrhea was defined as pelvic pain associated with any vaginal bleeding episode including cyclic and erratic bleeding. The VAS consisted of a nongraduated 100 mm line ranging from no pain to pain that is as bad as it could be. The score was measured using a ruler with a minimum measuring unit of 1 mm.
The follow-up visits occurred 1, 3, 6, 12, 15, 18, 21, 24, 27, and 30 months after treatment. The patients met with a gynecologist (B.-S.H. or Y.-H.C.) who performed a clinical examination and transvaginal ultrasonography and provided treatment as indicated.
The research nurse recorded the data regarding the dysmenorrhea VAS score, the noncyclic pelvic pain VAS score, and the predefined checklist of side effects. This step was undertaken to maintain the single-blind status (ie, the assessing nurse and outcome assessor were blinded to study allocation). The surgeons and participants were not blinded to study allocation.
The primary outcome was endometrioma recurrence assessed with sonography 1, 3, 6, 12, 15, 18, 21, 24, 27 , and 30 months after treatment. The secondary outcomes were the severity of the dysmenorrhea, the CA125 level, noncyclic pelvic pain, and side effects 30 months after surgery.
Endometrioma recurrence was defined via the ultrasound identification of a round mass with a thick wall, a minimum diameter of 3 cm, regular margins, and homogeneously lowechogenic fluid content with scattered internal echoes, without papillary projection and with absent or poor vascularization of capsule, and septa. 21 The use of levonorgestrel-releasing intrauterine system (LNG-IUS) does not fully inhibit ovulation. If an ultrasound scan suggested evidence of recurrence, sonography was repeated after 2 months to confirm the diagnosis of endometrioma recurrence. 9, 22 If a woman presented an apparent endometrioma on several scans that resolved on subsequent scans, she was not considered to have an endometrioma. If a patient had 2 ovarian endometriomas (each <3 cm in diameter), recurrence was recorded when the sum of the diameters was at least 3 cm. Because some studies defined the size of endometrioma recurrence as 2 cm, we also analyzed endometrioma recurrence defined via the ultrasound identification of a round mass with a thick wall, and a minimum diameter of 2 cm. 22 Dysmenorrhea recurrence was defined as a pain score greater than 50 mm after 3 months of postoperative pain relief. 6 The statistical analysis was performed with SPSS (version 21; IBM Inc, Armonk, NY). Descriptive statistics are presented as the medians (interquartile ranges), means AE SDs, or numbers with percentages. The c 2 test or Fisher exact test was performed to evaluate the discrete variables.
For continuous variables, we used a Student t test. All continuous variables were tested for normality with the Shapiro-Wilk's method. For variables that were not normally distributed, nonparametric statistical tests were used.
The data were compared using Mann-Whitney U tests for continuous data, and Wilcoxon signed rank tests were used for paired continuous data. The Kaplan-Meier method was used to calculate the cumulative probability that women would present with recurrent, dysmenorrhea, or ovarian endometriomas.
The hazard ratios (HRs) for recurrence were assessed with Cox proportional hazard models. The analyses of the efficacy outcomes were based on intentto-treat analyses, whereas side effects were analyzed using per-protocol analyses. A 2-tailed value of P < .05 was considered significant.
Results
A flow chart of study participant selection is provided in Figure 1 . Eighty-eight patients satisfied the eligibility criteria but 3 declined to participate in the trial, and 5 did not meet the inclusion criteria. These 5 patients did not show moderate and severe endometriosis or did not present a chocolate cyst during laparoscopic surgery. Histopathological tissue samples confirming the diagnoses of endometrioma were available in all 80 cases. The remaining 80 patients underwent randomization into the intervention group (n ¼ 40) or the control group (n ¼ 40) in the intention-to-treat analysis.
The baseline characteristics of the population are provided in Table 1 . The 2 groups were comparable in terms of age, obstetric history, weight, body mass index, largest endometrioma diameter, hemoglobin, CA125, dysmenorrhea pain, ASRM stage, and endometrioma laterality. All patients had the symptom of dysmenorrhea. The number of ultrasounds women underwent did not differ significantly between the 2 groups (intervention group vs control group, 9.2 AE 1.2, vs 9.3 AE 1.1, P ¼ .701).
There was no significant difference in the rates of endometrioma recurrence at 30 months between the 2 groups. Additionally, neither the largest diameters of the recurrent endometriomas nor the rates of bilateral recurrence differed significantly between the 2 groups. The distributions of the locations of the recurrent endometriomas (ie, ipsilateral or contralateral to the original endometrioma) did not differ between the 2 groups ( Table 2) .
In terms of endometrioma recurrence (size >3 cm), endometrioma recurrence at 30 months did not significantly differ between the 2 groups (the intervention group, 10 of 40, 25%, vs the control group, 15 of 40, 37.5%; HR, 0.60, 95% confidence interval [CI], 0.27e1.33, P ¼ .209; Figure 2A ).
In terms of endometrioma recurrence (size >2 cm), endometrioma recurrence at 30 months did not significantly differ between the 2 groups (the intervention group, 13 of 40, 32.5%, vs the control group, 17 of 40, 42.5%; HR, 0.68, 95% CI, 0.33e1.40, P ¼ .295; Supplemental Figure) .
A survival analysis using the KaplanMeier method revealed a significantly longer duration to dysmenorrhea recurrence in the intervention group ( Figure 2B ). Analgesic requirements were significantly higher in the control group (intervention vs control group, 17.5% vs 45%, P ¼ .008).
At 30 months after surgery, the VAS score for dysmenorrhea and noncyclic pelvic pain exhibited greater reductions in the intervention group than in the control group. At 30 months, the intervention group exhibited significantly lower dysmenorrhea and noncyclic pelvic pain VAS scores than the control group (Table 3) . At 30 months, the CA125 level exhibited greater reductions in the intervention group than in the control group (Table 3) .
The side effects of the medical treatments are presented in Table 4 .
Twenty-nine of the 40 patients in the intervention group (72.5%) and 18 of the 40 in the control group (45%) reported 1 or more side effects, and this difference was likely related to the levonorgestrel-releasing intrauterine system treatment (P ¼ .012).
The rate of irregular menstrual bleeding was significantly higher in the intervention group (27.5% vs 5%, P ¼ .006). Amenorrhea was also more common in the intervention group than in the control group (15% vs 0%, P ¼ .026).
The number-needed-to-treat benefit for dysmenorrhea recurrence was 5. The number of recurrent cases requiring further treatment in the intervention group (1 of 40, 2.5%) was significantly lower than that in the control group (8 of 40, 20%; P ¼ .031).
For the endometrioma recurrence cases in the control group, we offered reoperation or hormone treatment including oral contraceptive pills, gestrinone, or a levonorgestrel-releasing intrauterine system. For endometrioma recurrence in the intervention group, we offered reoperation, oral contraceptive pills, or gestrinone.
Finally, 1 endometrioma recurrence case in the intervention group required reoperation. Eight recurrence cases in the control group required further treatment: 3 required reoperations, and 5 were further treated with oral contraceptive pills (n ¼ 2), gestrinone (n ¼ 2), or the levonorgestrel-releasing intrauterine system (n ¼ 1).
Comment
The pathogenesis of recurrent endometrioma is not fully understood. There may be various factors that lead to the recurrence of endometrioma: the regrowth of residual lesions, ovulation, and de novo lesion because of retrograde menstruation. 23 According to literature review, the definition of endometrioma recurrence size was a cyst >2e3 cm, so we analyzed the endometrioma recurrence using both definitions.
Postoperative maintenance levonorgestrel-releasing intrauterine system therapy did not result in a longer duration until endometrioma The data are presented as the means AE SDs or the n (percentage) unless otherwise specified. The data were compared using a We also found that postoperative maintenance LNG-IUS therapy demonstrated significantly longer durations of dysmenorrhea recurrenceefree survival than GnRHa alone. Furthermore, postoperative maintenance LNG-IUS therapy significantly decreased the number of patients who required further treatment for recurrent disease compared with the control condition. However, the device could not inhibit ovulation or the regrowth of residual lesions.
Few studies have evaluated the longterm effectiveness of the device for 
FIGURE 2
Postlaparoscopic recurrence analyses using Kaplan-Meier tests to assess the differences in endometrioma (A) and dysmenorrhea (B) recurrence between the intervention and control groups. The hazard ratios for recurrence were assessed with Cox proportional hazard models Original Research GYNECOLOGY ajog.org preventing endometrioma recurrence. Wong et al 16 demonstrated that both LNG-IUS (n ¼ 15) and depot medroxyprogesterone acetate (n ¼ 15) administered for 3 years after laparoscopic ovarian cystectomy or oophorectomy can inhibit symptom recurrence. However, because this RCT study also included oophorectomy cases, it was difficult to isolate the long-term effects of LNG-IUS for endometrioma recurrence prevention. Furthermore, a high dropout rate was noted in the study; only 20 participants continued throughout the follow-up period.
In one cohort study comparing the efficacy of LNG-IUD and OCs for preventing endometrioma recurrence after laparoscopic conservative surgery, Cho et al 15 concluded that the postoperative use of an LNG-IUS seemed to be as effective as OCs for preventing endometrioma recurrence. However, the efficacy of LNG-IUS for preventing long-term endometrioma recurrence after conservative surgery is questionable because of a lack of welldesigned RCTs.
There are 3 possible reasons that maintenance levonorgestrel-releasing intrauterine system therapy did not inhibit endometrioma recurrence. First, the women who were treated with the device might have had a higher risk of ovarian cyst formation. 25 These deviceinduced ovarian cysts might have been misdiagnosed as endometriomas.
Second, it has been reported that ovulation is not suppressed in women who are treated with a levonorgestrelreleasing intrauterine system. 23 Conventional therapies for ovulation suppression, such as GnRHa, are provided not only to suppress estrogen production but also to inhibit ovulation. Although a levonorgestrel-releasing intrauterine system might induce anovulation in 71e85% of menstrual cycles in the first 3 months after insertion, the ovulation rate increases to more than 50% thereafter. 26 Third, the device cannot suppress the regrowth of residual endometrioma lesions. Conservative surgery is occasionally insufficient to completely remove the endometrioma lesion; therefore, lesions frequently redevelop postoperatively. 23 A maintenance levonorgestrel-releasing intrauterine system is not effective for preventing the endometrioma recurrence after laparoscopic cystectomy. Hence, long-term OC regimens are recommended to prevent endometrioma recurrence. 22, 27 There are 2 reasons for GnRHa and LNG-IUS given simultaneously. First, up to 1 in 5 LNG-IUS devices can be expelled from the uterine cavity after insertion. The greatest risk of this is during the first 6 weeks after insertion. The rate of expulsion is higher in nulliparous women. 28 Combined GnRHa and LNG-IU treatment reduced the device expulsion rate. 29 Second, postoperative medical therapies have been considered to reduce surgical treatment failures. If there is no postoperative adjuvant GnRHa therapy in the control group, the dropout rate will be higher in the control group. To examine the long-term efficacy of postoperative maintenance LNG-IUS for preventing endometrioma recurrence, GnRHas and LNG-IUS are given simultaneously in the intervention group.
The most common side effect of LNG-IUS is our study was unscheduled vaginal bleeding. Patterns included ajog.org GYNECOLOGY Original Research irregular secretory endometrium, a lack of proliferation, suppressed proliferation, and increases in the number of veins and the number of dilated veins at the endometrial/myometrial junction. The variety of histological findings further supports the difficulty of clearly identifying the etiology and determining an effective treatment approach. 30 The second most common side effect was amenorrhea. This likely is due to the strong endometrial suppression provoked by high local levonorgestrel concentrations within the endometrial cavity, leading to atrophy of the glandular epithelium. 31 There are some limitations to the present study. First, although the prevention of endometrioma recurrence is the ultimate goal of treatment, it is impossible to fully evaluate this therapeutic effect with any intervention because recurrent lesions are evaluated using ultrasonography rather than laparoscopy with histological confirmation. 21 Second, double blinding was not performed in our study. A true doubleblind study would be quite difficult to perform. 6 Although the investigator tried to mask the patients in the intervention group, most of the patients in the intervention group (92.6%) correctly guessed which group they were in because the levonorgestrel-releasing intrauterine system causes various types of abnormal uterine bleeding. 6 Therefore, the present study was not a double-blind study. Consequently, some bias in favor of the treatment group may have been introduced.
Third, a major confounder of this study is that some of the secondary outcomes (for example, dysmenorrhea) may have been period related rather than endometriosis related. 32 Fourth, the numbers of cases and adverse events were small and the study was not sufficiently powered to assess the side effects.
Fifth, to avoid possible confounding factors, it is reasonable to apply strict inclusion criteria to maintain clinical homogeneity. However, a large number of exclusion criteria would have limited the population of patients who could have been included in this study (ie, the exclusion of those with prior surgery, preoperative hormone therapy use, etc would have excluded many patients who are seen in a typical endometriosis practice). The recurrence rate in intervention group was higher than the expected recurrence. The possible reason is that endometrima size in our study is larger than those of a previous study (55.9 AE 20.3 mm vs 42 AE 21 mm). 15 Compared with the retrospective study by Chao et al, 15 we exactly evaluated the endometrioma recurrence by regular sonography follow-up. Thus, a larger RCT or a nationwide population-based cohort study is needed to assess the real practical situation.
Sixth, although the follow-up period was described as 30 months in our study, maybe the true follow-up period is 24 months. Because all of the patients received GnRHa for at least 6 month, no recurrence was detected during the first 6 months.
In conclusion, the use of a maintenance levonorgestrel-releasing intrauterine system is not effective for preventing the endometrioma recurrence after laparoscopic cystectomy surgery. n 
SUPPLEMENTAL FIGURE
Postlaparoscopic recurrence analyses using Kaplan-Meier tests to assess the differences in endometrioma recurrence (cyst size, >2 cm) between the intervention and control groups. The hazard ratios for recurrence were assessed with Cox proportional hazard models Original Research GYNECOLOGY ajog.org
